Co-targeting therapy did not further enhance neutrophil infiltration in KPC mT3 tumors than Gem-treatment, but co-targeting increased the IFN-γ-responsive and Sell+ neutrophil subset (cluster 1, Fig. 7f, g; Supplementary Fig. S13c–e), which was recently shown to be involved in anti-tumor activities and response to immunotherapies51,52. This evidence concerns the gene SELL and neoplasm.